Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10711029B2 · kind B2 · utility
0Cited by
0References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 14, 2017 |
| Grant date | Jul 14, 2020 |
| Priority date | — |
| Expiry date | Jul 14, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX and Formula X that are highly active against the HCV virus when administered in an effective amount to a host in need thereof. The host can be a human or any animal that carries the viral infection. Methods of treating a subject suffering from a condition related to viral infections are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.